Market: NASD |
Currency: USD
Address: 3805 Old Easton Road
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
📈 Aprea Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$10.50
-
Upside/Downside from Analyst Target:
538.30%
-
Broker Call:
4
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
10-25%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2023 |
- |
$0.050000 |
- |
2023-02-13 |
- |
Stock split |
|
Total Amount for 2023: $0.050000 |
📅 Earnings & EPS History for Aprea Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2025-08-12 | -0.53 |
| 2025-03-25 | -0.49 |
| 2024-11-07 | -0.64 |
| 2024-08-12 | -0.58 |
| 2024-05-14 | -0.67 |
| 2024-03-26 | -0.92 |
| 2023-11-09 | -0.86 |
| 2023-08-10 | -0.87 |
| 2023-05-15 | -1.34 |
| 2023-03-30 | -0.92 |
| 2022-11-09 | -2.4 |
| 2022-08-11 | -19.63 |
📰 Related News & Research
No related articles found for "aprea therapeutics".
